A one-time treatment. The potential for lifelong impact.

Orchard is building on decades of research and advancements in the field of gene therapy to develop potential cures for rare and often-fatal diseases. Our ex vivo autologous gene therapy approach is designed to use a person’s own blood stem cells and insert into those cells a working copy of the missing or faulty gene. By giving these gene-corrected cells to the patient, we aim to permanently correct genetic disorders with a single treatment.

This approach relies on the intrinsic ability of blood stem cells, also known as hematopoietic stem cells or HSCs, to self-renew in a patient’s bone marrow and produce new blood cells of all types. Our approach also avoids the need for a bone marrow transplant, which uses cells from a donor and can result in serious complications including graft-versus-host disease.

Learn more about our gene therapy approach:

Step 1
Cells are collected from the patient

The patient’s own (“autologous”) blood stem cells, also called hematopoietic stem cells (HSCs), are harvested either through a peripheral blood procedure known as “leukapheresis” or by extracting bone marrow.

Step 2
Blood stem cells are selected and purified

Once outside the body, special blood-forming HSCs are selected. These are the cells we want to correct as they can develop into many different cell types in the blood.

Step 3
A working copy of the gene is inserted into the cells

We use a particular type of virus, a lentivirus that has been disabled from multiplying, to insert a working copy of the missing or faulty gene into the cells. This process happens outside of the body, or ex vivo, in a laboratory. The corrected cells are then frozen, or cryopreserved.

Step 4
The patient is conditioned to receive treatment

The patient undergoes a conditioning regimen that clears the defective hematopoietic stem cells from the bone marrow and makes space for the genetically corrected cells to engraft.

Step 5
The gene-corrected cells are infused into the patient

The gene-corrected cells are transported to a treatment center, then thawed and infused into the patient intravenously. Once the cells engraft in the bone marrow, they begin to self-renew and produce healthy blood cells of all types. Some of these cells are able to cross the blood-brain barrier and potentially achieve a therapeutic effect in the brain.

Our approach will potentially make a profound difference in the lives of those affected by certain rare, inherited diseases. To date, more than 150 people have been treated in clinical trials with our ex vivo autologous gene therapies across six different disease areas, with up to 18 years post-treatment follow-up in some conditions. 

The site uses cookies to provide you with a more responsive and personalized service. By using this site, you agree to our use of cookies as set out in our cookie policy.

Please read our privacy policy and cookie policy for more information on the cookies we use and how to delete or block the use of cookies.
I agree to using cookies

Notice:

Orchard Therapeutics is not responsible for the content of external Internet sites.

If you wish to continue, click “Continue”, or otherwise click “Stay on page”

Continue to: Stay on page X